- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04108455
Biomarkers During Pregnancy
May 4, 2023 updated by: Washington University School of Medicine
Alternate Biomarkers for Better Management of Diabetes During Pregnancy and Prediction of Neonatal Complications in Pregnant Women With Diabetes
This study aims to obtain preliminary data for utility of alternate biomarkers for monitoring glucose control in diabetic women during pregnancy and/or predicting risk of adverse neonatal events in these women.
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Detailed Description
This study aims to obtain preliminary data for utility of alternate biomarkers for monitoring glucose control in diabetic women during pregnancy and/or predicting risk of adverse neonatal events in these women.
Our population is unique compared to published studies and contains significant numbers of African American women and overweight or obese women.
Two of these markers have been examined in several other populations of pregnant women and have shown utility for both outcomes.
However, the recommended levels of these markers need to be determined in specific populations as ethnicity and BMI affect the values.
Values obtained in recruited women will be compared with biobank samples from women who have no evidence or history of diabetes.
Additionally, two other potentially promising markers will be examined (beta-hydroxybutyrate and triglycerides).
Both these analytes change during pregnancy and beta-hydroxybutyrate has shown correlation with large for gestational status or macrosomia in some studies.
A combination of markers may be a better predictor of adverse neonatal outcomes than a single marker.
Study Type
Observational
Enrollment (Actual)
47
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University in St Louis
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 48 years (Child, Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Our study population includes a large percentage of African Americans as well as a significant percentage of women with BMI ≥30.
All women enrolled in the study will be pregnant and have been diagnosed with diabetes.
Description
Inclusion Criteria:
- All women included in the study will either have diabetes diagnosed before pregnancy or will have been diagnosed during pregnancy (GDM). We do not exclude minors, since in Missouri, they may consent to medical treatment without parental consent for medical issues relating to pregnancy,
Exclusion Criteria:
- No specific exclusion criteria will be used. BMI data will be collected and utilized to sort patients into various subgroups, but will not be used as exclusion criteria.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
With Diabetes
Pregnant women with diabetes - either diagnosed beforehand or diagnosed during gestation
|
Serum will be collected from patients at multiple times during pregnancy for later analysis.
|
Controls
Biobank samples will be obtained from similar age/BMI/ethnicity women who do not have evidence of diabetes.
|
Serum will be collected from patients at multiple times during pregnancy for later analysis.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glucose Control
Time Frame: up to 60 weeks from enrollment
|
various measures of glucose control will be reported and compared to other biomarkers measured by the study
|
up to 60 weeks from enrollment
|
Adverse Neonatal Events
Time Frame: up to 60 weeks from enrollment
|
various adverse neonatal events will be reported and compared to other biomarkers measured by the study
|
up to 60 weeks from enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glycated Albumin
Time Frame: up to 60 weeks from enrollment
|
Levels of % glycated albumin will be measured in the various cohorts to see if correlations exist with glucose control and adverse neonatal events
|
up to 60 weeks from enrollment
|
Glycated Serum Protein (GSP)
Time Frame: up to 60 weeks from enrollment
|
Levels of glycated serum protein will be measured in the various cohorts to see if correlations exist with glucose control and adverse neonatal events
|
up to 60 weeks from enrollment
|
Beta-hydroxybutyrate
Time Frame: up to 60 weeks from enrollment
|
Levels of beta-hydroxybutyrate will be measured in the various cohorts to see if correlations exist with glucose control and adverse neonatal events
|
up to 60 weeks from enrollment
|
Triglycerides
Time Frame: up to 60 weeks from enrollment
|
Levels of triglycerides will be measured in the various cohorts to see if correlations exist with glucose control and adverse neonatal events
|
up to 60 weeks from enrollment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 15, 2019
Primary Completion (Actual)
November 1, 2021
Study Completion (Anticipated)
November 30, 2023
Study Registration Dates
First Submitted
September 25, 2019
First Submitted That Met QC Criteria
September 26, 2019
First Posted (Actual)
September 30, 2019
Study Record Updates
Last Update Posted (Estimate)
May 5, 2023
Last Update Submitted That Met QC Criteria
May 4, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201808125
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gestational Diabetes
-
IRCCS Burlo GarofoloCompletedGestational Diabetes | Gestational Diabetes Mellitus | Pregnancy-Induced Diabetes | Diabetes Mellitus, Gestational | Diabetes, Pregnancy InducedIsrael, Italy, Netherlands, Slovenia, Sri Lanka
-
UPECLIN HC FM Botucatu UnespCompletedGestational Diabetes Mellitus | Pregestational Diabetes Mellitus | Mild Gestational HyperglycemiaBrazil
-
Assistance Publique - Hôpitaux de ParisCompleted
-
McGill University Health Centre/Research Institute...The Lawson FoundationCompletedGestational Diabetes Mellitus With Baby DeliveredCanada
-
Woman'sBaton Rouge Area FoundationCompletedGestational Diabetes MellitusUnited States
-
Baylor College of MedicineRecruitingGestational Diabetes MellitusUnited States
-
Joslin Diabetes CenterRoche DiagnosticsCompletedGestational Diabetes MellitusUnited States
-
Ludwig-Maximilians - University of MunichGerman Federal Ministry of Education and Research; Helmholtz Zentrum MünchenCompletedGestational Diabetes MellitusGermany
-
Assiut UniversityUnknownGestational Diabetes Mellitus
-
Brigham and Women's HospitalUniversity of Colorado, DenverCompletedGestational Diabetes MellitusUnited States
Clinical Trials on Specimens Collected
-
Aristotle University Of ThessalonikiUniversity of Southampton; National and Kapodistrian University of AthensNot yet recruitingCoronary Artery Disease | Aortic Valve Disease | STEMI | Cardiovascular Pathology | Aortic Valve Calcification
-
Institut Claudius RegaudRecruitingCervical Cancer | Head and Neck Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Anal Cancer | Cervical Intraepithelial Neoplasia 3 | Glioblastoma Multiforme of Brain StemFrance
-
Zhejiang Cancer HospitalRecruitingCholangiocarcinoma | Biliary Tract TumorChina
-
Memorial Sloan Kettering Cancer CenterJohns Hopkins University; M.D. Anderson Cancer Center; Mayo Clinic; Baylor College... and other collaboratorsCompleted
-
Istituto Clinico HumanitasUnknown
-
University of OxfordSanpasitthiprasong Hospital; Mahidol Oxford Tropical Medicine Research UnitRecruiting
-
University of NebraskaCompletedKidney Failure, ChronicUnited States
-
Hadassah Medical OrganizationCompleted
-
Memorial Sloan Kettering Cancer CenterUnited States Department of DefenseCompletedRenal Cell Carcinoma | Cholangiocarcinoma | Malignant Pleural Mesothelioma (MPM) | Choroidal Nevus | Primary Uveal Melanoma (UM) | Metastatic Uveal Melanoma (UM)United States